{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:36:08Z","timestamp":1780101368712,"version":"3.54.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Celiac disease (CD) is one of the most common gluten-related disorders. Although the only effective treatment is a strict gluten-free diet, doubts remain as to whether healthcare professionals take this restriction into consideration when prescribing and dispensing medicines to susceptible patients. This scoping review aimed to find out the current evidence for initiatives that either describe the gluten content of medicines or intend to raise awareness about the risk of prescribing and dispensing gluten-containing medicines in patients with CD and other gluten-related disorders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A scoping review was conducted using three search strategies in PubMed\/MEDLINE, TripDatabase and Web of Science in April 2021, following the PRISMA extension for scoping reviews (PRISMA-ScR). References from included articles were also examined. Two researchers screened the articles and results were classified according to their main characteristics and outcomes, which were grouped according to the PCC (Population, Concept and Context) framework. The initiatives described were classified into three targeted processes related to gluten-containing medicines: prescription, dispensation and both prescription and dispensation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified a total of 3146 records. After the elimination of duplicates, 3062 articles remained and ultimately 13 full texts were included in the narrative synthesis. Most studies were conducted in the US, followed by Canada and Australia, which each published one article. Most strategies were focused on increasing health professional\u2019s knowledge of gluten-containing\/gluten-free medications (<jats:italic>n<\/jats:italic>\u2009=\u20098), which were basically based on database development from manufacturer data. A wide variability between countries on provided information and labelling of gluten-containing medicines was found.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Initiatives regarding the presence of gluten in medicines, including, among others, support for prescribers, the definition of the role of pharmacists, and patients\u2019 adherence problems due to incomplete labelling of the medicines, have been continuously developed and adapted to the different needs of patients. However, information is still scarce, and some aspects have not yet been considered, such as effectiveness for the practical use of solutions to support healthcare professionals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-021-01772-9","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T17:03:17Z","timestamp":1628355797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gluten in pharmaceutical products: a scoping review"],"prefix":"10.1186","volume":"10","author":[{"given":"Irene","family":"Lizano-D\u00edez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-6285","authenticated-orcid":false,"given":"Pilar","family":"Modamio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"key":"1772_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2011-301346","volume":"62","author":"JF Ludvigsson","year":"2013","unstructured":"Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62:43\u201352.","journal-title":"Gut"},{"key":"1772_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","volume":"16","author":"P Singh","year":"2018","unstructured":"Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:823\u201336.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1772_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000369518","volume":"33","author":"C Catassi","year":"2015","unstructured":"Catassi C, Gatti S, Lionetti E. World perspective and celiac disease epidemiology. Dig Dis. 2015;33:141\u20136.","journal-title":"Dig Dis"},{"key":"1772_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(17)31796-8","volume":"391","author":"B Lebwohl","year":"2018","unstructured":"Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. 2018;391:70\u201381.","journal-title":"Lancet"},{"key":"1772_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.dld.2016.10.016","volume":"49","author":"L Elli","year":"2017","unstructured":"Elli L, Villalta D, Roncoroni L, et al. Nomenclature and diagnosis of gluten-related disorders: a position statement by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Dig Liver Dis. 2017;49:138\u201346.","journal-title":"Dig Liver Dis"},{"key":"1772_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40273-018-0707-5","volume":"37","author":"ES Mearns","year":"2019","unstructured":"Mearns ES, Taylor A, Boulanger T, et al. Systematic literature review of the economic burden of celiac disease. Pharmacoeconomics. 2019;37:45\u201361.","journal-title":"Pharmacoeconomics"},{"key":"1772_CR7","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1331\/JAPhA.2008.08014","volume":"48","author":"RA Mangione","year":"2008","unstructured":"Mangione RA, Patel PN. Caring for patients with celiac disease: the role of the pharmacist. J Am Pharm Assoc. 2008;48:e125\u201335.","journal-title":"J Am Pharm Assoc"},{"key":"1772_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467\u201373.","journal-title":"Ann Intern Med"},{"key":"1772_CR9","unstructured":"Peters M, Godfrey C, McInerney P, et al. The Joanna Briggs Institute reviewers\u2019 manual 2015: methodology for JBI scoping reviews; 2015."},{"key":"1772_CR10","first-page":"114","volume":"133","author":"DG Patel","year":"1985","unstructured":"Patel DG, Krogh CM, Thompson WG. Gluten in pills: a hazard for patients with celiac disease. Can Med Assoc J. 1985;133:114\u20135.","journal-title":"Can Med Assoc J"},{"key":"1772_CR11","doi-asserted-by":"crossref","unstructured":"Challen RG, O\u2019Shannassy RM. Gluten content of Australian pharmaceutical products. Med J Aust. 1987;146:91\u20133.","DOI":"10.5694\/j.1326-5377.1987.tb136272.x"},{"key":"1772_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1310\/hpj4402-105","volume":"44","author":"AR King","year":"2009","unstructured":"King AR. The Impact of celiac sprue on patients\u2019 medication choices. Hosp Pharm. 2009;44:105\u20136.","journal-title":"Hosp Pharm"},{"key":"1772_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1310\/hpj4411-984","volume":"44","author":"AR King","year":"2009","unstructured":"King AR. Gluten content of the top 200 medications of 2008: A follow-up to the impact of celiac sprue on patients\u2019 medication choices. Hosp Pharm. 2009;44:984\u201392.","journal-title":"Hosp Pharm"},{"key":"1772_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1310\/hpj4809-736","volume":"48","author":"AR King","year":"2013","unstructured":"King AR. Gluten content of the top 200 medications: follow-up to the influence of gluten on a patient\u2019s medication choices. Hosp Pharm. 2013;48:736\u201343.","journal-title":"Hosp Pharm"},{"key":"1772_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2146\/ajhp140153","volume":"72","author":"JE Cruz","year":"2015","unstructured":"Cruz JE, Cocchio C, Lai PT, et al. Gluten content of medications. Am J Health Syst Pharm. 2015;72:54\u201360.","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"1772_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1310\/hpj4511-841","volume":"45","author":"AR King","year":"2010","unstructured":"King AR. The influence of gluten on a patient\u2019s medication choices. Hosp Pharm. 2010;45(11):841\u20133.","journal-title":"Hosp Pharm"},{"key":"1772_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/ajhp\/58.5.396","volume":"58","author":"JP Crowe","year":"2001","unstructured":"Crowe JP, Falini NP. Gluten in pharmaceutical products. Am J Health Syst Pharm. 2001;58:396\u2013401.","journal-title":"Am J Health Syst Pharm"},{"key":"1772_CR18","first-page":"30","volume":"36","author":"RA Mangione","year":"2011","unstructured":"Mangione RA, Patel PN. Pharmaceutical care of celiac disease. US Pharm. 2011;36:30\u20133.","journal-title":"US Pharm"},{"key":"1772_CR19","doi-asserted-by":"crossref","unstructured":"Avena-Woods C, Mangione RA, Wu WK. Exploring the community pharmacist\u2019s knowledge of celiac disease. Am J Pharm Educ. 2018;82:100\u20135.","DOI":"10.5688\/ajpe6353"},{"key":"1772_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00005176-199407000-00005","volume":"19","author":"ID Miletic","year":"1994","unstructured":"Miletic ID, Miletic VD, Sattely-Miller EA, Schiffman SS. Identification of gliadin presence in pharmaceutical products. J Pediatr Gastroenterol Nutr. 1994;19:27\u201333.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1772_CR21","unstructured":"Jay L, Mangione RA. Gluten in medication: qualifying the extent of exposure to people with celiac disease and identifying a hidden and preventable cause of an adverse drug event. National Foundation for Celiac Awareness (NFCA); 2014. Grant number 4288."},{"issue":"5","key":"1772_CR22","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s11096-016-0368-4","volume":"38","author":"H Urwin","year":"2016","unstructured":"Urwin H, Wright D, Twigg M, et al. Early recognition of coeliac disease through community pharmacies: a proof of concept study. Int J Clin Pharm. 2016;38(5):1294\u2013300.","journal-title":"Int J Clin Pharm"},{"key":"1772_CR23","first-page":"58","volume":"31","author":"S Plogsted","year":"2007","unstructured":"Plogsted S. Medications and celiac disease - tips from a pharmacist. Pract Gastroenterol. 2007;31:58\u201364.","journal-title":"Pract Gastroenterol"},{"key":"1772_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jpainsymman.2006.01.002","volume":"31","author":"S Esteban","year":"2006","unstructured":"Esteban S, Podder N, Cruciani R. Celiac disease: not all medications are contaminated with gliadin. J Pain Symptom Manage. 2006;31:195\u20136.","journal-title":"J Pain Symptom Manage"},{"key":"1772_CR25","unstructured":"Committee for Medicinal Products for Human Use. Annex to the European Commission guideline on \u2018Excipients in the labelling and package leaflet of medicinal products for human use\u2019 (SANTE-2017\u201311668). European Medicines Agency (EMA); 2017. Available at: https:\/\/www.ema.europa.eu\/en\/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human. Accessed 18 Dec 2019."},{"key":"1772_CR26","unstructured":"The Spanish Agency of Medicines and Medical Devices (AEMPS). Circular N\u00b0 1\/2018: Updated information about excipients in the labelling of medicinal products for human use. Ministry of Health, Consumption and Social Welfare: The Spanish Agency of Medicines and Medical Devices; 2018. [In Spanish]. Available at: https:\/\/www.aemps.gob.es\/informa\/circulares\/medicamentosUsoHumano\/2018\/docs\/circular_1-2018-actualizacion-excipientes-medicamentos.pdf. Accessed 8 Dec 2019."},{"key":"1772_CR27","unstructured":"U.S. Department of Health and Human Services: Food and Drug Administration (FDA). Gluten in Drug Products and Associated Labeling Recommendations Guidance for Industry (draft guidance). Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER); 2017. Available at: https:\/\/www.fda.gov\/media\/116958\/download. Accessed 20 Mar 2020."}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-021-01772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-021-01772-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-021-01772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T17:03:47Z","timestamp":1628355827000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-021-01772-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1186\/s13643-021-01772-9","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}